Todas as matérias desta categoria, das mais recentes às mais antigas.
Zenas BioPharma (NASDAQ:ZBIO) announced that it is on track to transition into a commercial-stage company, with plans to submit its first Biologics License Application (BLA) to the U.S. Food and Drug Administration this quarter.
Atour Lifestyle Holdings (NASDAQ:ATAT) reported a robust start to fiscal year 2026, delivering triple-digit profit momentum and aggressive top-line growth.
National Vision Holdings (NASDAQ:EYE) delivered a sharp increase in profitability for the first quarter of 2026, as successful pricing initiatives and a shift toward managed care customers bolstered the company’s bottom line.
Boyd Group Services (NYSE:BGSI) delivered record-breaking financial results for the first quarter of 2026, as the company reaped the initial benefits of its transformative $1.3 billion acquisition of Joe Hudson’s Collision Center.
Regis Corporation (NASDAQ:RGS) demonstrated improved operational efficiency in its third fiscal quarter, reporting a significant rise in net income and earnings per share despite a contraction in its top-line revenue.
WeRide (NASDAQ:WRD) reported record unaudited financial results for the first quarter of 2026, as the company’s aggressive international expansion into fare-charging robotaxi services began to scale.
Birkenstock Holding (NYSE:BIRK) revealed a surge in quarterly sales that matched its aggressive growth ambitions, though bottom-line results were pinched by escalating trade costs and unfavorable currency movements.
Alibaba Group Holding (NYSE:BABA) reported a complex set of financial results for the quarter and fiscal year ended March 31, 2026, revealing a company in the midst of an expensive strategic pivot.
UCloudlink Group (NASDAQ:UCL) recorded a contraction in its financial performance for the first quarter of 2026, marked by declining top-line revenue and a return to negative adjusted earnings.
Kyivstar (NASDAQ:KYIV) reported a robust start to fiscal year 2026, characterized by a significant acceleration in digital service adoption and strong double-digit growth across its core financial metrics.
Takeda Pharmaceutical (NYSE:TAK) reported fiscal year 2025 results that met its revised management guidance, as the company utilized aggressive operational savings to buffer the impact of generic competition for its top-selling ADHD medication, Vyvanse.
Innate Pharma (NASDAQ:IPHA), a clinical-stage biotechnology company specializing in immuno-oncology, announced its business update and consolidated financial results for the quarter ended March 31, 2026.
